Literature DB >> 19688697

Animal models and different therapies for treatment of retinitis pigmentosa.

Miren Agurtzane Rivas1, Elena Vecino.   

Abstract

Retinitis pigmentosa (RP) is a heterogeneous group of retinal degenerative diseases initially affecting the rod photoreceptor. Patients present with night blindness, loss of peripheral vision and finally the loss of central vision, as a consequence of death of cone photoreceptors. RP is a genetic disease, showing inheritance of autosomal dominant (AD), autosomal recessive (AR) or X-linked (XL) recessive traits, although some patients have no family history of RP (simplex RP). Many animal models of RP are available and have led to a better understanding of the pathology of the disease, and to the development of therapeutic strategies aimed at curing or slowing down the genetic disorder. In this review, we describe the selected animal models (natural and transgenic) and their phenotypes and genotypes, as well as the advantages and disadvantages of the use of each animal. Also, we look at different therapeutic strategies being studied worldwide and report the latest results. Nevertheless, many obstacles will have to be overcome before most of these strategies can be applied to humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688697     DOI: 10.14670/HH-24.1295

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  27 in total

1.  Optimization of in vivo confocal autofluorescence imaging of the ocular fundus in mice and its application to models of human retinal degeneration.

Authors:  Peter Charbel Issa; Mandeep S Singh; Daniel M Lipinski; Ngaihang V Chong; François C Delori; Alun R Barnard; Robert E MacLaren
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-29       Impact factor: 4.799

Review 2.  Applications of CRISPR/Cas9 in retinal degenerative diseases.

Authors:  Ying-Qian Peng; Luo-Sheng Tang; Shigeo Yoshida; Ye-Di Zhou
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

3.  Changes in morphology and visual function over time in mouse models of retinal degeneration: an SD-OCT, histology, and electroretinography study.

Authors:  Tomoko Hasegawa; Hanako O Ikeda; Noriko Nakano; Yuki Muraoka; Tatsuaki Tsuruyama; Keiko Okamoto-Furuta; Haruyasu Kohda; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2016-01-05       Impact factor: 2.447

Review 4.  Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases.

Authors:  Melissa K Jones; Bin Lu; Sergey Girman; Shaomei Wang
Journal:  Prog Retin Eye Res       Date:  2017-01-19       Impact factor: 21.198

Review 5.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

6.  Rod and cone photoreceptor cells produce ROS in response to stress in a live retinal explant system.

Authors:  Lavinia Bhatt; Gillian Groeger; Kieran McDermott; Thomas G Cotter
Journal:  Mol Vis       Date:  2010-02-23       Impact factor: 2.367

Review 7.  General pathophysiology in retinal degeneration.

Authors:  Katherine J Wert; Jonathan H Lin; Stephen H Tsang
Journal:  Dev Ophthalmol       Date:  2014-04-10

Review 8.  A role of Heat Shock Protein 70 in Photoreceptor Cell Death: Potential as a Novel Therapeutic Target in Retinal Degeneration.

Authors:  Ayako Furukawa; Yoshiki Koriyama
Journal:  CNS Neurosci Ther       Date:  2015-10-28       Impact factor: 5.243

9.  N-methyl-N-nitrosourea-induced retinal degeneration in mice is independent of the p53 gene.

Authors:  Katsuhiko Yoshizawa; Maki Kuwata; Ayako Kawanaka; Norihisa Uehara; Takashi Yuri; Airo Tsubura
Journal:  Mol Vis       Date:  2009-12-30       Impact factor: 2.367

Review 10.  Emerging gene therapies for retinal degenerations.

Authors:  Constance L Cepko
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.